[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518142":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":18,"locations":10,"responsibleParty":28,"collaborators":10,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":36,"eligibilityCriteria":37,"healthyVolunteers":32,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":10,"studyType":44,"phases":10,"briefSummary":45,"conditions":46,"keywords":10,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":10},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients treated for acute cerebrovascular pathology cerebrovascular disease",null,[12],"Other: follow-up",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":10},"follow-up","Long term follow-up",[9],[19,24],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Peggy Reiner, Dr","CONTACT","+33149956525","peggy.reiner@aphp.fr",{"name":25,"role":21,"phone":26,"phoneExt":10,"email":27},"Jérôme Lambert, Dr","+33142499742","jerome.lambert@u-paris.fr",{"type":29,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100518142","cohort-of-neurovascular-diseases-treated-in-the-acute-phase-and-followed-at-lariboisire-100518142",false,"NCT06026696","Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière","Cohorte de Maladies Neurovasculaires Prises en Charge à la Phase aiguë et Suivies à Lariboisière","NERVAL","Inclusion Criteria:\n\n1. Adult patients ≥18 years\n2. Patients admitted to the Neurovascular Intensive Care Unit with acute cerebrovascular disease OR Patients managed for acute cerebrovascular pathology with or without stroke by the Lariboisière neurology team.\n3. No opposition from the patient to the research and for patients under guardianship or guardianship or lack of capacity to object (severe impairment of cognitive functions, dementia, etc.), no opposition from the legal representative.\n\nExclusion Criteria:\n\n1. Patient refusing to take part in the study or refusal by the legal representative in the case of patients under guardianship or curatorship\n2. Patient suffering from a rare neurovascular disease and being followed at the \"Centre de référence des maladies vasculaires rares du cerveau et de l'oeil\" (CERVCO)","ALL","18 Years","100 Years",{"count":42,"type":43},5000,"ESTIMATED","OBSERVATIONAL","Neurovascular diseases can cause ischaemic or haemorrhagic strokes. While the most common, such as atherosclerosis are widely studied, others are less well known, such as arterial dissections or cerebral angiopathies. What's more, most studies are limited to a few years' follow-up and the longer-term evolution of patients is less well assessed. Patient follow-up data available in routine practice and specific enrollment through the headache emergencies of the Lariboisière neurovascular intensive care unit (USINV) could provide a particularly rich resource.",[47,48],"Ischemic Stroke","Hemorrhagic Stroke","NOT_YET_RECRUITING","2023-09-04",{"date":52,"type":53},"2023-09-07","ACTUAL",{"date":55,"type":43},"2023-09",{"date":57,"type":43},"2038-09",{"name":5,"class":6}]